Take a closer look at the full table. The average price to earnings ratio (P/E ratio) amounts to 17.35 while the forward price to earnings ratio is 10.13. The dividend yield has a value of 3.28 percent. Price to book ratio is 2.81 and price to sales ratio 2.93. The operating margin amounts to 22.48 percent.
Best Stocks For 2014: Cobra Electronics Corporation(COBR)
Cobra Electronics Corporation engages in the design and marketing of two-way mobile communication and mobile navigation products in the United States, Canada, and Europe. It operates in two segments, Cobra Consumer Electronics and Performance Products Limited. The Cobra Consumer Electronics segment principally offers radar detection products, photo-enforcement and safety detection products, citizens band radios, power inverters and jumpstarters, two-way radios, and marine electronics, as well as mobile navigation for professional drivers. It sells its products directly to retailers, such as mass marketers, consumer electronics specialty stores, department store chains, warehouse clubs, television home-shopping and internet retailers, direct-response merchandisers, home centers, specialty stores, and travel center, as well as through two-step wholesale distributors that carry its products to fill orders for travel centers, small department stores and appliance dealers, duty -free shops on cruise lines, and export and marine products. The Performance Products Limited segment offers personal navigation devices under the Snooper Truckmate, Snooper Ventura, Snooper Sapphire Plus, and other trade names; GPS-enabled speed camera location detectors under the Snooper My Speed, Snooper 3 Zero, and other trade names; proprietary AURA database that provides drivers with advance notice of upcoming speed camera and hazard locations; E-Bike, a compact folding electric bike; and WPT250M tracker, a tracking device that uses GPS, GPRS, and GSM technology to monitor the location of boats, vehicles, pets, or individuals with an accuracy of 2.5 meters. The company was founded in 1961 and is based in Chicago, Illinois.Best Stocks For 2014: Vera Bradley Inc.(VRA)
Vera Bradley, Inc., through its subsidiary, Vera Bradley Designs, Inc., engages in the design, production, marketing, and retail of functional accessories for women under the ?Vera Bradley? brand. Its products include a range of handbags, accessories, and travel and leisure items. The company sells its products to independent retailers located in the United States, as well as to national retailers and third party e-commerce sites. As of January 29, 2011, Vera Bradley, Inc. sold its products directly through 35 full-price stores, 4 outlet stores, verabradley.com, and an annual outlet sale in Fort Wayne, Indiana. The company was founded in 1982 and is headquartered in Fort Wayne, Indiana.Advisors' Opinion:
- [By Stockpickr]One final earnings short-squeeze play is Vera Bradley (VRA), set to release numbers on Tuesday after the market close. This is a designer, producer, marketer and retailer of accessories for women. The products include offering of handbags, accessories and travel and leisure items. Wall Street analysts, on average, expect Vera Bradley to report revenues of $96.82 million.
I like this stock for a post-earnings short-squeeze play because the bears have cleaned up on this name recently in a big way. This stock has dropped dramatically from its May high of $52.35 a share to its current low of $24.83 a share. That huge drop could be setting up this stock for a sharp rebound if the bulls hear what they're looking for.
The current short interest as a percentage of the float for Vera Bradley is an extremely large 29.5%. That means that out of the 19.74 million shares in the tradable float, 5.83 million are sold short by the bears. It's worth pointing out that the bears have been increasing their bets from the last reporting period by 10.5%, or by around 554,000 million shares. If the bears are pressing too much ahead of this quarter, then this stock could easily see a big short-squeeze.
From a technical standpoint, the stock is currently trading significantly below both its 50-day and 200-day moving averages, which is bearish. That said, the stock just found some buying support at around $25 a share and has since bounced up towards its current price of around $29 a share.
I would look to be a buyer of this stock after they report if it trades above $30 to $31.56 a share on strong volume. Look for volume the following day that's tracking in close to or greater than its three-month average action of 582,000 shares. I would target a run back towards $35 a share (50-day) or possible $38 a share (200-day) if the bulls gain full control of this stock post-earnings.
I would only short this name if it drops below $25 a share on big volume after the company reports its results. I would add to any bearish bets if it then drops below $22.50 a share and ride this stock down with the short-sellers.
Best Stocks For 2014: Impax Laboratories Inc.(IPXL)
Impax Laboratories, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and marketing of bioequivalent pharmaceutical products. The company operates in two divisions, Global Pharmaceuticals and Impax Pharmaceuticals. The Global Pharmaceuticals division develops, manufactures, sells, and distributes generic pharmaceutical products. It provides its generic pharmaceutical prescription products directly to wholesalers and retail drug chains; and generic pharmaceutical over-the-counter and prescription products through unrelated third-party pharmaceutical entities. The Impax Pharmaceutical division develops proprietary brand pharmaceutical products that address central nervous system disorders, including Alzheimer?s disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinson?s disease, and schizophrenia, as well as promotes third-party branded pharmaceutical products. As of May 2, 2011, the com pany marketed 101 generic pharmaceuticals, which represent dosage variations of 29 different pharmaceutical compounds; and another 16 of its generic pharmaceuticals representing dosage variations of 4 different pharmaceutical compounds. It markets and sells its generic pharmaceutical prescription drug products in the continental United States and the Commonwealth of Puerto Rico. The company has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V. Impax Laboratories, Inc. was founded in 1993 and is headquartered in Hayward, California.Advisors' Opinion:
- [By Michael Shulman]The not-so-small generic drug maker Impax Laboratories (NASDAQ: IPXL) has arguably the best manufacturing technology for time-released drugs in the entire generic industry.
Pfizer’s (NYSE: PFE) patent for its $11 billion cholesterol drug Lipitor expires this year, and we know IPXL believes it has the expertise to manufacture a sophisticated statin such as Lipitor given recent legal actions concerning Merck’s drug Vytorin, a combination of a competing statin and a blood pressure drug. In other words, IPXL has the technical expertise to enter this market should it choose to do so.
Two other major product introductions are anticipated in 2011 — generic Concerta for ADHD and generic Solodyn for bacterial infections, currently with combined sales of $1.8 billion.
My target for the stock is $35-$40 in one to two years. IPXL is also the possible target of an acquirer.
No comments:
Post a Comment